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Morphologyrelative proportions of type I and II collagens and IIA procollagen in full depth
biopsies of repair tissue in a large sample of patients treated with autologous chondrocyte implantation
(ACI). Sixty ﬁve full depth biopsies were obtained from knees of 58 patients 8–60 months after treatment by
ACI alone (n=55) or in combination with mosaicplasty (n=10). In addition articular cartilage was
examined from eight individuals (aged 10–50) as controls. Morphology and semi-quantitative immunohis-
tochemistry for collagen types I and II and procollagen IIA in the repair tissue were studied. Repair cartilage
thickness was 2.89±1.5 mm and there was good basal integration between the repair cartilage, calciﬁed
cartilage and subchondral bone. Sixty ﬁve percent of the biopsies were predominantly ﬁbrocartilage (mostly
type I collagen and IIA procollagen), 15% were hyaline cartilage (mostly type II collagen), 17% were of mixed
morphology and 3% were ﬁbrous tissue (mostly type I collagen). Type II collagen and IIA procollagen were
usually found in the lower regions near the bone and most type II collagen was present 30–60 months after
treatment. The presence of type IIA procollagen in the repair tissue supports our hypothesis that this is
indicative of a developing cartilage, with the ratio of type II collagen:procollagen IIA increasing from b2% in
the ﬁrst two years post-treatment to 30% three to ﬁve years after treatment. This suggests that cartilage
repair tissue produced following ACI treatment, is likely to take some years to mature.
© 2009 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Damaged articular cartilage is known to be less capable of repair
than most other tissues in the body due to the absence of a vascular
system, the immobility of chondrocytes and the limited ability of
mature chondrocytes to proliferate and regenerate new cartilage [1,2].
However, various surgical techniques have been developed to
stimulate biological repair, such as microfracture, subchondral
drilling, osteochondral autologous transplantation (OATS or mosaic-
plasty) or autologous chondrocyte implantation (ACI [3]). The latter is
the most commonly used cell-based therapy for the treatment of
cartilage defects in the young human [4,5]. The objective of these
procedures is to stimulate autologous cells to synthesise components
of articular cartilage and to organize them in a manner resembling
that seen in normal articular cartilage.
Type II collagen makes up more than 90% of the collagen found in
adult articular (hyaline) cartilage [6] and it occurs to a smaller extentobert Jones and Agnes Hunt
. Tel./fax: +44 1691 404664.
s).
-NC-ND license. in ﬁbrocartilage tissue such as the intervertebral disc and the
meniscus. In contrast, type I collagen is either present in very small
amounts or is absent from hyaline cartilage but is abundant in
ﬁbrocartilage [7–9]. These ﬁbrillar collagens are synthesized from
larger, precursor procollagen molecules. Type II procollagen has been
shown to exist in two forms generated by alternative splicing of the
precursor mRNAs: type IIA procollagen, which contains a region of a
cysteine-rich NH2 propeptide consisting of 69 amino acids, and type
IIB procollagen in which this extra propeptide is absent [10,11]. Type
IIB procollagen is synthesized by mature, fully differentiated chon-
drocytes whilst type IIA is thought to be produced by chondropro-
genitor cells (e.g. chondrogenic mesenchymal and perichondrium
cells) [12]. The extra 69 amino acid domain in the procollagen type IIA
propeptide has been shown to bind with bone morphogenetic growth
factors including BMP-2 and TGF-β. This has led to a suggested role for
procollagen IIA of binding growth factors in the developing chondro-
genic matrix [12].
Investigators have found that different surgical methods result in
varying types of repair tissue. For example, ﬁbrocartilage often forms
after subchondral drilling and microfracture [13,14], whereas follow-
ing ACI a mixture of hyaline and ﬁbrocartilage occurs, with a greater
presence of type II collagen reported [15], particularly in the deep zone
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time after ACI treatment [18], with 45% of patients demonstrating
hyaline cartilage more than 18 months post-ACI compared to 24% at
earlier time points [19]. The presence of hyaline tissue containing type
II collagen in post-ACI repair correlated with good to excellent clinical
results [15,19,20]. Therefore, it has been assumed that the presence of
type II collagen is the ideal aim for healthy hyaline cartilage [9]. Whilst
type II collagen has been reported in repair tissue [21], this alone is not
an indication of hyaline cartilage as it can be common in ﬁbrocartilage,
such as the intervertebral disc (where it can constitute 80% of the total
collagen) [7]. Hence, the presence of type II collagen alone is not an
adequate marker of hyaline cartilage repair.
Studies to date have been carried out on either relatively small
samples or with limited histological information [3,9,15–18,21–28].
The aim of the present study was to carry out a comprehensive
histological study of the repair tissue formed in a large sample of
patients treated with ACI for chondral defects or ACI and mosaicplasty
for osteochondral damage and attempt to determine the proportion of
collagen types I and II. In addition, type IIA procollagen was
investigated, to test the hypothesis that the repair tissue would
resemble developing cartilage found in young, immature articular
cartilage.Fig. 1. (a) Good integration of the repair tissue with the underlying bone (B) was a very comm
old male; 13 months post-ACI). Vascularisation (arrow) was an infrequent occurrence (c; 39
old male, 21 months post-ACI treatment). H&E stained sections.2. Materials and methods
Sixty ﬁve full depth biopsies were obtained from 58 patients (at an
average age of 34±9.8 years) who had been treated with ACI for
cartilage defects according to the method of Brittberg et al. [3]; 10 of
these had osteochondral defects with damage to the bone of more
than 3 mm in depth and thus received ACI in combination with
mosaicplasty (carried out as one procedure). Arthroscopic examina-
tion and biopsy of the graft were performed at approximately
12 months (mean 15.7±10.7, range 8–60 months), as approved by
the local Ethical Committee. Biopsies of 1.8 mm in diameter were
taken (using a juvenile bone marrow biopsy needle) from the centre
of the treated region and included both the repair cartilage tissue and,
where possible, the subchondral bone, as detailed previously [17]. A
mapping system is used at all stages of ACI in our centre, ensuring
accurate sampling location of the biopsy [29]. Thirty-ﬁve biopsies
were taken from the left knee and 30 from the right. Forty ﬁve biopsies
were taken from the medial femoral condyle which was the most
common site of treatment, 16 biopsies from the lateral femoral
condyle, three from the trochlea and one from the patella. For
comparison, ‘normal’ articular cartilage was examined from indivi-
duals aged 19 and 33 years from femoral heads obtained at autopsy,on ﬁnding. This is clearly visible when viewedwith polarized light (b) (a and b: 40 year
year old male, 16 months post-ACI treatment), as was mineralization (d; arrow; 25 year
Table 1
Percentage area of repair tissue stained immunopositively for antibodies against collagen
types I, II or procollagen IIA.
Collagen All samples ACI alone ACI+mosaicplasty ‘Control’
cartilage
I 90.9±22.3 (65) 90.9±23.9 (55) 89.8±23.3 (10) 1.7±0.8 (8)
II 60.0±31.3 (65) 56.8±33.8 (55) 72.8±24.0 (10) 100±0.1 (8)
Procollagen IIA 45.5±35.5 (54) 44.4±37.1 (46) 47.0±27.5 (8) 1.2±0.4 (5)
Results are means±standard deviationwith number of samples analysed in parentheses.
Fig. 3. The percentage of the sections of repair cartilage which was immunopositive for
the collagens I, II or procollagen IIA varied according to morphology, in comparison to
normal articular cartilage. Bars represent standard error of the mean.
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22, 30, 40 and 50 years obtained at autopsy and from the ankle joints
of individuals aged 10 and 13 years undergoing corrective surgery.
The biopsy samples were either snap frozen and stored in liquid
nitrogen, or ﬁxed in formalin, decalciﬁed and parafﬁn embedded until
processing for histology and immunohistochemistry. Frozen sections
(7 µ thick) or wax sections (4 µ thick) were cut and stained with
haematoxylin and eosin (H&E) or toluidine blue to assess morphology
and the degree of metachromatic staining (as a crude assessment of
glycosaminoglycan content), respectively. If any samples appeared to
havemineralizationwithin the repair cartilage on H&E stained sections,
this was conﬁrmed by von Kossa staining on frozen sections [30].
Sections were viewed under normal bright ﬁeld illumination and
polarized light, as recommended by the International Cartilage Repair
Society [31]. Other histological parameters were assessed and scored,
the sumof themgiving anoverall semi-quantitative ‘OsScore’, whichwe
have used previously [17]. A maximum score of 10 corresponded to
normal adult articular cartilage. These parameters included the integrity
of the articular surface, integration with the underlying bone, the pres-
ence of ectopic mineralization or vascularisation within the cartilage,
thedegreeof cell clustering,metachromasia and themorphologyor type
of repair cartilage present. Tissue morphology was classiﬁed as pre-
dominantly hyaline, predominantly ﬁbrocartilage, a mixture of the two
(mixed) or ﬁbrous tissue with no true cartilage present, as described
previously [17,28]. Hyaline cartilage was clearly differentiated from
ﬁbrocartilage by the homogenous appearance of thematrix, particularly
when viewed under polarized light, and the round or oval shape of the
cells, often surrounded by lacunae. Fibrocartilage, in contrast, had ob-
vious bundles of collagen ﬁbres lying in a random, irregularmanner and
often more elliptical shaped cells.
Tissue sections were ﬁxed on a slide if frozen or de-waxed if they
were parafﬁn embedded, followed by treatment with hyaluronidase
(Sigma; 4800 U/ml in 0.025M NaCl 0.05M sodium acetate pH 5.0, 2 h
at RT for frozen sections) or hyaluronidase and trypsin (Sigma; 0.1%
hyaluronidase and 0.2% trypsin 1 h 37 °C for wax sections) to unmask
the collagen antigens [17]. Sections were then incubated for 1 h at
room temperature with primary antibodies against type I collagen
(monoclonal antihuman, clone no 1-8H5; ICN) and against type II
collagen (CIICI; Developmental Studies Hybridoma Bank, Iowa, USA)Fig. 2. Immunostaining for type IIA procollagen was frequently strong in the cells closest to
control; 46 year old female 14 months post-ACI.or overnight with a polyclonal antibody raised in rabbits against type
IIA procollagen [32]. Type IIA procollagen immunostaining was only
performed on frozen sections, whilst either frozen or wax sections
were used for immunostaining of type I and II collagens. Endogenous
peroxidase was blocked with 0.3% hydrogen peroxide in methanol
before sections were incubated with the biotinylated secondary
antibody, either anti-mouse (for collagen types I and II primary
antibody) or anti-rabbit (for type IIA procollagen). The signal was
ampliﬁed using an avidin–biotin–peroxidase reagent (Vectastain Elite
ABC kit; Vector Laboratories, Peterborough, UK) and labelling was
visualized with diaminobenzidine as substrate. Sections were then
washed, dehydrated, and mounted in pertex. ‘Control’ sections of
biopsy samples were treated either with normal mouse IgG, normal
rabbit serum or phosphate buffered saline alone, in place of the
primary antibodies and then treatment continued in the same way as
all the other slides.
The degree of immunohistochemical labelling was assessed semi-
quantitatively bymeasuring the areas of the repair cartilage, on adjacent
sectionswherepossible,whichwere immunostained for collagen types I
and II and type IIA procollagen. Images were captured using an
Optivision Image Capture system. The area of positive staining was
delineated and this was calculated as a percentage of the total area of
uncalciﬁed cartilage. Calculations were performed using an image
analysis system (Aequitas 1a, Dynamic Data Links, Cambridge, UK). The
coefﬁcient of variance for these measurements was 1.1%.
Non-parametric statistical analyses (Mann–Whitney U test and
Spearman rank (rs) correlations) were carried out using a softwarethe calciﬁed cartilage (CC) and bone. (a,b) Type IIA procollagen and (c) normal rabbit
Fig. 4. A biopsy obtained from a 32 year old, 60 months post-ACI treatment (a–c) showed little staining for either types I (a) or IIA procollagen (c), whereas there was
immunopositivity for type II collagen throughout, apart from at the surface (b). B: Bone.
Fig. 5. (a) The percentage of sections of repair cartilage immunopositive for collagens I,
II or procollagen IIA at different time intervals post-treatment. (b) The ratio of areas
immunostained with type II:type IIA procollagen increased signiﬁcantly with time after
treatment (⁎p=0.005). Bars represent standard error of the mean.
401S. Roberts et al. / The Knee 16 (2009) 398–404programme (Analyse-it Software Ltd, Leeds, UK). Means are quoted±
standard deviation.
3. Results
The repair cartilage was on average 2.89 mm (±1.5, range 0.2–7.8) in thickness
(compared to 1.8 mm±0.6 for the control cartilage). Morphological analysis of all the
biopsy samples revealed that 63% (41/65) of the biopsies were predominantly
ﬁbrocartilage, 23% (15/65) mixed (ﬁbrocartilage and hyaline cartilage) morphology,
10.8% (7/65) predominantly hyaline cartilage and 3.1% (2/65) ﬁbrous tissue. There was
no apparent difference between locations treated. Of the 11 biopsies from patients
treated with mosaicplasty in combinationwith ACI, a predominance of hyaline cartilage
was seen in two, ﬁbrocartilage in ﬁve and mixed morphology in four. This was in
comparison to the samples of ‘normal’ articular cartilage (both cadaveric and surgical),
which were all hyaline cartilage throughout, with no variation between locations.
The surface integrity and smoothness was normal or near normal in 75% of samples
and abnormal in 25%. Eighty two percent of the biopsies included the underlying bone
and in all cases there was good basal integration between the repair cartilage, calciﬁed
cartilage and subchondral bone (Fig. 1a). A minority of sections showed vascularisation
and mineralization (Fig. 1b–c) in the repair tissue, occurring in 12% of the biopsies for
both parameters.Whenmineralizationwas present it was usually in very discrete, small
areas. The overall OsScore for all repair biopsies was 6.6±1.7 (n=65, range 2.5–10),
whilst the ‘normal’ samples scored 9.7±0.4 (range 9.2–10).
Immunohistochemistry results demonstrated some immunopositivity for type I and
II collagens to varying extents in all patient samples, whilst all but two stained for
procollagen IIA. The percentage of the area stained for each antibody is shown inTable 1;
treatment with ACI and mosaicplasty combined appeared to have little effect on the
results, apart from having slightly more type II collagen (probably from the implanted
core). The pattern of immunostaining for type IIA procollagenwas typically in the lower
part of the core, close to the calciﬁed cartilage and bone; sometimes it was throughout
the matrix (weakly), but it was more commonly cell associated (Fig. 2). ‘Normal’
articular cartilage sampleswere immunopositive for type II collagenwith no staining (or
atmost a thin strip at the surface) for type I collagen. Procollagen IIA, in contrast, showed
an apparent age-related difference in distribution in the ‘normals’. The cartilage from
younger individuals (13 years of age and less) was weakly positive throughout the
matrix with stronger pericellular staining around cells in the deeper zones. A similar but
weaker patternwas seen in cartilage from the 19 year old but therewas little staining in
any samples from older individuals.
The percentage of areas of normal articular cartilage immunopositively stained for
collagen type I was 1.7% and for type II collagen was 100%. This is in accordance with
biochemical measures of 0.2% of the total collagen in articular cartilage being type I
collagen and 96% being type II [33]. The predominant type of collagen in the repair tissue
in our study varied signiﬁcantly with different cartilage morphologies and these are
displayed in Fig. 3. The greatest area of immunostaining for type I collagen was seen in
ﬁbrous tissue and ﬁbrocartilage and least in hyaline cartilage (pb0.0001), whereas the
greatest area of immunostaining for type II collagen was in the hyaline cartilage repair
tissue and least in ﬁbrous and ﬁbrocartilaginous repair (pb0.001 between hyaline and
ﬁbrocartilage). Whilst 63%±44, (n=29) of the area of ﬁbrocartilage and 48%±32,
(n=5) of hyaline cores stained for type IIA procollagen, the difference was not
signiﬁcant. There was, however, some correlation in the areas that immunostained for
type II collagen and type IIA procollagen (rs=0.62; p=b0.0001), as expected, partly
due to the presence of the epitope recognized by the type II antibody in the procollagen.There was a difference in the areas, which were immunopositive for the collagen
types in cores taken at different intervals after treatment (Fig. 4). The percentage of
areas of sections staining positively for type I collagen or type IIA procollagen were the
least at three or more years post-treatment whilst for type II collagen it was greater
Fig. 6.Most samples which were ﬁbrocartilaginous or mixed morphology (as viewed with polarized light) were immunopositive for type I throughout (a) with some type II in the
lower region (b). In contrast tissue of hyalinemorphologywas strongly stained for type II collagen (e) in thematrix with little type I (d). Procollagen IIAwas seen both in the cells and
the pericellular matrix in the deep zone (c,f). (a, b 25 year old male 20 months post-ACI; c 58 year old male, 14 months post-ACI; d–f 42 year old female, 11 months post-treatment).
B: Bone; CC: calciﬁed cartilage.
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greater (at 30.1%±31.4; p=0.005) at 3 years post-ACI than at 12 months when it was
1.8%±2.7 (Fig. 5b). Seventy-ﬁve percent (±21, n=5) of the area of biopsies was
immunopositive for type II collagen in those taken more than 36 months after
treatment whereas it was 52%±42 (n=9) of the area in those taken less than
12 months after.
In some samples the repair tissue was completely immunopositive for all three
antibodies used. For others, particularly where ﬁbrocartilage predominated, staining
was present throughout the core for type I collagen (Fig. 6a) whilst collagen type II and
procollagen IIA staining was restricted to the lower regions (Fig. 6b and c). In contrast,
other samples, particularly those that were mostly hyaline cartilage, had little staining
for type I collagen compared to types II or IIA (Fig. 6d–f). If staining for type II collagen
and type IIA procollagen did not occur throughout the complete core, then it was most
frequently found towards the lower region of the core in the cartilage nearest the bone.
There was often a great deal of overlap of regions positive for collagen types I, II and IIA
procollagen.
4. Discussion
This study provides the most extensive histological examination of
a large series of biopsies from ACI-treated patients to date. In addition,
the complete area from articulating surface to the bone, has been
assessed semi-quantitatively for themake-up of the ﬁbrillar collagens,
types I and II, in addition to procollagen IIA.
All samples showed good basal integration with the underlying
bone; this is the trend with human ACI repair and unlike the situation
in animal models in which there is often poor and incomplete
integration with the host tissue [34,35]. This species difference maydepend to some extent on post-operative loading, since the type of
motion applied to cartilage repair systems has been shown to be very
important in vitro [36]. The relevance of mineralization and vascular-
isation in the repair tissue is not known. Certainly neither is a feature
of normal articular cartilage. These parameters were sought and
included in the histological score, OsScore (as negative features),
speciﬁcally because the periosteum, which is used in traditional ACI, is
a potentially active tissue and can lead to calciﬁcation or have blood
vessels within it. One might expect that vascularisation and/or
mineralization of the repair tissue could lead to its premature
degradation. However, there is no evidence from this or other studies
to date of the deleterious effect of either.
The proportion of samples which were hyaline or a mixture of
hyaline and ﬁbrocartilage morphology in this study (35%) is not so
dissimilar to that reported by Bartlett et al. [27]: 44% in ACI and 36% in
matrix autologous chondrocyte implantation (MACI) or 48% of ACI
with hyaluronan [19]. Parameters used in our centre to classify
morphology are fairly stringent in comparison to many other studies.
Tissue, which under normal bright light microscopy may appear
hyaline (i.e. with oval chondrocyte-like cells in lacunae, sparsely
populating the matrix), can often be clearly demonstrated to be
ﬁbrocartilage if viewed with polarized light. In addition, in our centre
we obtain and assess the full depth of repair tissue, which is not the
case in all reports [28,31]. It might be expected that biopsies from
patients treated with the combination of mosaicplasty and ACI would
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from patients who underwent this combined treatment, only two
were classiﬁed as hyaline. This may have arisen because biopsies were
taken from areas between the transplanted cores, a situation which
occurred for two likely reasons: (1) defects treated in this manner had
fewer transplanted cores (covering approximately 50% of the area)
than if treated with mosaicplasty alone, and (2) the ‘intercore’ area
was targeted for biopsy to some extent because it was a region of
particular interest to monitor post-treatment events. Unfortunately
we were not able to assess the lateral integration of the repair and
adjacent tissue microscopically in this study, as the biopsy was taken
from the central region as recommended by the ICRS [29].
Those samples that were hyaline in nature had more immunopo-
sitivity for type II collagen than type I or type IIA procollagen and, as
we have found previously, the hyaline tissue occurred in the lower
zones nearer the bone. In addition, as expected, the predominantly
ﬁbrous and ﬁbrocartilage cores stained throughout for type I collagen,
whilst areas of staining for types II and IIAwere smaller and restricted
to the lower zones of these samples. This study highlights the
important fact that repair cartilage which is of ﬁbrocartilage
morphology contains a signiﬁcant proportion of type II collagen;
hence type II collagen alone is not a sufﬁcient indication of hyaline
cartilage regeneration. Development of type II collagen production
appeared to increase with time after ACI repair (59% and 69% of areas
were immunopositive at b12 and 30–60 months, respectively),
but this was not signiﬁcant. The presence of a large amount of im-
munostaining for type I collagen in what is classiﬁed as hyaline
cartilage may be surprising and it is certainly more than would be
expected for mature adult human articular cartilage.
Type IIA procollagen is important in cartilage development [37,38],
particularly in the early stages [39]. Type IIA procollagen, together
with the mRNA transcript, is re-expressed by adult articular
chondrocytes in the mid zone of osteoarthritic cartilage, whilst
neither is found in normal adult articular cartilage (over the age of
40 years) [11]. It is not currently clear whether the procollagen of
osteoarthritic cartilage has a role in repair but it is comparable to the
foetal chondroprogenitor phenotype observed in embryonic develop-
ment [11] and suggests that early phases of repair involve re-
expression of a developmental sequence by chondrocytes [40]. During
chondrogenesis the expression of type IIA procollagen by chondro-
progenitor cells precedes the expression of type IIB procollagen
(‘mature’ type II collagen) by chondrocytes and chondroblasts. Hence
the correlation between the area of cores immunopositive for type II
collagen and type IIA procollagen is not surprising. The fact that the
ratio of collagen II:IIA is so much higher at 3–5 years post-treatment
than at 12 months suggests that IIA procollagen here really is
indicative of chondrogenesis rather than a marker of osteoarthritis
as is sometimes suggested [41]. The distribution of staining for type IIA
in the repair biopsies, i.e. often being pericellular, particularly in the
lower zones, is similar to the distribution seen in the younger samples
of ‘normal’ cartilage examined here and also to the only other report of
type IIA expression in cartilage repair tissue [21]. The presence of type
IIA procollagen in 96% of our biopsies of ACI-treated sites is thus
indicative of a developing cartilage with a high degree of cellular
activity. This supports other studies on similar samples where other
markers demonstrated an active remodelling process [18] and tissue
maturation [19] on-going in the repair site [33]. Since type IIA
procollagen contains a chordin-like repeat which binds growth factors
including TGFβ and BMP-2, its presence could potentially facilitate a
speedier production of matrix molecules and in-ﬁlling of the defect. In
addition, BMP-2 is capable of reversing the de-differentiation of
chondrocytes, such that it potentiates the expression of the mature
type IIB procollagen by chondrocytes [41].
This study has limitations in that we have used immunohisto-
chemistry to assess the amount of different collagen types within
cartilage repair tissue. This is not a truly quantitative method [9] asuniform thickness of tissue in the sections cannot be guaranteed, nor
the stoichiometry of the antibody labelling and staining procedure. In
addition, the biopsy specimens are necessarily small and from a very
discrete part of the treated region — no more than 1% of its total area.
Hence one could question how representative and useful such a small
area is. Nonetheless, this method does provide much information
about the distribution of the components of the repair tissue and an
indication of the degree of staining for them.
In summary, results from our study demonstrate replacement of
chondral defects, which have been treated with ACI, with cartilage
tissue in 97% of cases. The immunostaining of the deeper zones of
biopsied material was generally typical of hyaline cartilage, being
positive here for type II collagen in 96% of samples. In contrast, the
presence of type II collagen was less in repair tissue of ﬁbrocartilage
morphology; here, and in ﬁbrous tissue, type I collagen immunostain-
ing was most common. Type IIA procollagen was present in both
hyaline and ﬁbrocartilage tissue, indicating a high degree of activity in
the process of cartilage repair. Thus this supports our hypothesis that
the repair tissue does indeed resemble young, immature cartilage and
has chondrogenic potential. We would suggest that the same
sequence of events which happens in the developing skeleton, i.e.
mesenchymal cells switching expression from type I collagen to IIA
and to IIB procollagen (i.e. mature type II collagen) [39], is happening
with time in this repair cartilage. If the formation of true hyaline
cartilage with predominantly type II collagen is important to function,
then this may explain the good long term clinical results reported by
Peterson et al. [15] for ACI at 9 years post-treatment.
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